MetaCap

ABVC BioPharma (ABVC) vs BriaCell Therapeutics (BCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BriaCell Therapeutics (BCTX) has outperformed ABVC BioPharma (ABVC) over the past year, losing 61.7% versus a loss of 67.8%. Over five years, BCTX leads with a -97.0% price change compared with -97.3% for ABVC. BriaCell Therapeutics is the larger company by market cap ($26.7 million vs $23.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVC-67.80%BCTX-61.75%
+65%-8%-80%
Nov 21, 20251 yearNov 20, 2026
ABVC-97.37%BCTX-97.12%
+20%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVC versus BCTX key metrics
MetricABVCBCTX
Share price$0.8663$3.06
Market cap$23.37M$26.72M
1-day change-1.56%-3.32%
YTD return-59.33%-56.96%
1-year return-67.80%-61.75%
5-year return-97.29%-97.00%
EPS (TTM)$-0.20$-6.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$296.00K—
Revenue growth (YoY)-41.91%—
Net income (latest FY)$-7.91M$-34.90M
Operating margin-2415.97%—
Net margin-2671.81%—
52-week high$2.87$13.09
52-week low$0.707$2.60
Distance from 52-week high-69.82%-76.62%
Average volume81.92K250.81K
Shares outstanding26.98M8.73M
Employees16—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ABVC BioPharma

ABVC stock →

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

ABVC vs BCTX FAQ

Which is bigger, ABVC BioPharma or BriaCell Therapeutics?

BriaCell Therapeutics (BCTX) is larger, with a market capitalization of $26.72M compared with $23.37M for ABVC BioPharma (ABVC).

Which stock has performed better over the past year, ABVC or BCTX?

BCTX returned -61.75% over the past 12 months, compared with -67.80% for ABVC (price return, excluding dividends). Past performance does not predict future results.

Are ABVC BioPharma and BriaCell Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons